Glenmark Pharmaceuticals Limited has launched new diabetes medicine of fixed-dose combination (FDC) to contain Teneligliptin with Pioglitazone. The brand name Zita Plus Pio has Teneligliptin (20 mg) + Pioglitazone (15 mg) to be taken once a day. The only DPP4 and Glitazone combination brand in India is for adults with uncontrolled Type 2 diabetes.

• GMR Airports Gears up for Next Phase of Growth; Launches New Operations Centre 
• Sai Life Sciences Ltd IPO GMP & Lot Size Details : Worth Investing Or Not?
• BEML Shares Rally 4% on Securing a Rs 136 Crore Order 
• Haber Raises $44 Million Through a Series C Funding Round 
• Alembic Pharma Clears Brazilian Health Regulator Audit

“Diabetes is a key area of focus for Glenmark, a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients,” said Alok Malik, Group Vice President & Head, India, Founder of Glenmark Pharmaceutical.

Fixed-Dose Combination (FDC) is innovated by Glenmark and is approved by DCGI (Drug Controller General of India). The drug named Teneliglitptin with Pioglitazone will be helpful for diabetes patients, which improves glycemic control reducing Insulin Resistance.